Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis

Eleonora Virgilio; Domizia Vecchio; Ilaria Crespi; Roberto Serino; Roberto CANTELLO; Umberto DIANZANI; Cristoforo COMI

doi:10.1016/j.msard.2021.103231

Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis

Eleonora Virgilio, Domizia Vecchio, Ilaria Crespi, Roberto Serino, Roberto CANTELLO, Umberto DIANZANI, Cristoforo COMI

Research output: Contribution to journal › Article › peer-review

Abstract

Axonal loss is an important feature of Multiple Sclerosis (MS), being strongly related to irreversible disability accumulation. Nonetheless, the exact mechanisms underlying axonal loss remain unclear. Cerebrospinal fluid (CSF) levels of Tau and Beta-amyloid (Abeta) currently represent diagnostic biomarkers in other neurodegenerative diseases. In MS, studies on CSF Tau and Abeta provided preliminary informations on disease prognosis, but results have not yet been replicated.

Original language	English
Pages (from-to)	103231
Journal	Multiple Sclerosis and Related Disorders
Volume	56
DOIs	https://doi.org/10.1016/j.msard.2021.103231
Publication status	Published - 2021

Keywords

Amyloid beta-Peptides
Axons
Biomarker
Biomarkers
Humans
Magnetic Resonance Imaging
Multiple Sclerosis
Multiple sclerosis
Neurodegeneration
Prognosis
Tau
tau Proteins

Access to Document

10.1016/j.msard.2021.103231

http://hdl.handle.net/11579/141068

Cite this

@article{edb2f4a363a44536a67b1899f7bfa242,

title = "Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis",

abstract = "Axonal loss is an important feature of Multiple Sclerosis (MS), being strongly related to irreversible disability accumulation. Nonetheless, the exact mechanisms underlying axonal loss remain unclear. Cerebrospinal fluid (CSF) levels of Tau and Beta-amyloid (Abeta) currently represent diagnostic biomarkers in other neurodegenerative diseases. In MS, studies on CSF Tau and Abeta provided preliminary informations on disease prognosis, but results have not yet been replicated.",

keywords = "Amyloid beta-Peptides, Axons, Biomarker, Biomarkers, Humans, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple sclerosis, Neurodegeneration, Prognosis, Tau, tau Proteins, Amyloid beta-Peptides, Axons, Biomarker, Biomarkers, Humans, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple sclerosis, Neurodegeneration, Prognosis, Tau, tau Proteins",

author = "Eleonora Virgilio and Domizia Vecchio and Ilaria Crespi and Roberto Serino and Roberto CANTELLO and Umberto DIANZANI and Cristoforo COMI",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

doi = "10.1016/j.msard.2021.103231",

language = "English",

volume = "56",

pages = "103231",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis

AU - Virgilio, Eleonora

AU - Vecchio, Domizia

AU - Crespi, Ilaria

AU - Serino, Roberto

AU - CANTELLO, Roberto

AU - DIANZANI, Umberto

AU - COMI, Cristoforo

PY - 2021

Y1 - 2021

N2 - Axonal loss is an important feature of Multiple Sclerosis (MS), being strongly related to irreversible disability accumulation. Nonetheless, the exact mechanisms underlying axonal loss remain unclear. Cerebrospinal fluid (CSF) levels of Tau and Beta-amyloid (Abeta) currently represent diagnostic biomarkers in other neurodegenerative diseases. In MS, studies on CSF Tau and Abeta provided preliminary informations on disease prognosis, but results have not yet been replicated.

AB - Axonal loss is an important feature of Multiple Sclerosis (MS), being strongly related to irreversible disability accumulation. Nonetheless, the exact mechanisms underlying axonal loss remain unclear. Cerebrospinal fluid (CSF) levels of Tau and Beta-amyloid (Abeta) currently represent diagnostic biomarkers in other neurodegenerative diseases. In MS, studies on CSF Tau and Abeta provided preliminary informations on disease prognosis, but results have not yet been replicated.

KW - Amyloid beta-Peptides

KW - Axons

KW - Biomarker

KW - Biomarkers

KW - Humans

KW - Magnetic Resonance Imaging

KW - Multiple Sclerosis

KW - Multiple sclerosis

KW - Neurodegeneration

KW - Prognosis

KW - Tau

KW - tau Proteins

KW - Amyloid beta-Peptides

KW - Axons

KW - Biomarker

KW - Biomarkers

KW - Humans

KW - Magnetic Resonance Imaging

KW - Multiple Sclerosis

KW - Multiple sclerosis

KW - Neurodegeneration

KW - Prognosis

KW - Tau

KW - tau Proteins

UR - https://iris.uniupo.it/handle/11579/141068

U2 - 10.1016/j.msard.2021.103231

DO - 10.1016/j.msard.2021.103231

M3 - Article

SN - 2211-0348

VL - 56

SP - 103231

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

ER -

Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this